EU greenlights Dupixent for chronic urticaria, offering new hope to patients
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Surgical site infections and antimicrobial resistance remain major challenges globally
Subscribe To Our Newsletter & Stay Updated